Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
IMMP 
Immutep Ltd ADR (IMMP)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/03/2025: IMMP (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $9.5
1 Year Target Price $9.5
| 1 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -55.37% | Avg. Invested days 22 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/03/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 270.83M USD | Price to earnings Ratio - | 1Y Target Price 9.5 |
Price to earnings Ratio - | 1Y Target Price 9.5 | ||
Volume (30-day avg) 2 | Beta 1.84 | 52 Weeks Range 1.32 - 2.71 | Updated Date 12/2/2025 |
52 Weeks Range 1.32 - 2.71 | Updated Date 12/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.3 |
Earnings Date
Report Date 2025-12-03 | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -2035.47% |
Management Effectiveness
Return on Assets (TTM) -22.66% | Return on Equity (TTM) -36.88% |
Valuation
Trailing PE - | Forward PE 7.65 | Enterprise Value 200551896 | Price to Sales(TTM) 53.7 |
Enterprise Value 200551896 | Price to Sales(TTM) 53.7 | ||
Enterprise Value to Revenue 803.42 | Enterprise Value to EBITDA -2.94 | Shares Outstanding 147192034 | Shares Floating 1222246969 |
Shares Outstanding 147192034 | Shares Floating 1222246969 | ||
Percent Insiders 0.01 | Percent Institutions 2.18 |
Upturn AI SWOT
Immutep Ltd ADR
Company Overview
History and Background
Immutep Ltd (IMMP) is an Australian biotechnology company founded in 2001. It focuses on the research, development, and commercialization of immunotherapeutic products for the treatment of cancer and autoimmune diseases. It has undergone several stages of development, focusing on LAG-3 related immunotherapy.
Core Business Areas
- LAG-3 Immunotherapy: Immutep develops therapies targeting the LAG-3 (Lymphocyte Activation Gene-3) immune control point to activate the immune system to fight cancer and autoimmune diseases.
Leadership and Structure
Immutep is led by a management team with expertise in biotechnology and pharmaceuticals. The organizational structure includes research and development, clinical operations, and commercial functions. Dr. Fru00e9du00e9ric Triebel is the Chief Scientific Officer and Chief Medical Officer.
Top Products and Market Share
Key Offerings
- Eftilagimod Alpha (Efti): Efti is Immutep's lead product candidate, a soluble LAG-3 protein. It is being evaluated in various clinical trials for different cancer types, often in combination with other therapies. Specific market share data is not publicly available as the product is not yet approved for commercial sale. Key competitors include companies developing similar immunotherapies such as Merck (Keytruda) and Bristol Myers Squibb (Opdivo).
Market Dynamics
Industry Overview
The immunotherapy market is a rapidly growing segment of the pharmaceutical industry. It focuses on harnessing the body's own immune system to fight diseases, particularly cancer. Increasing cancer incidence and advancements in biotechnology are driving market growth.
Positioning
Immutep is positioned as a leader in LAG-3 immunotherapy, a novel approach to cancer treatment. Its competitive advantage lies in its proprietary LAG-3 technology and its clinical development programs.
Total Addressable Market (TAM)
The global immunotherapy market is projected to reach hundreds of billions of dollars. Immutep, with its focus on LAG-3, targets a significant portion of this market. The exact TAM portion specific to LAG-3 is hard to define precisely, but it's expected to grow substantially as LAG-3 therapies gain acceptance.
Upturn SWOT Analysis
Strengths
- Proprietary LAG-3 technology
- Strong patent portfolio
- Clinical trials showing promising results
- Experienced management team
Weaknesses
- Reliance on clinical trial success
- Lack of approved products
- Limited financial resources compared to larger pharmaceutical companies
- High risk associated with drug development
Opportunities
- Potential for FDA approval of Efti
- Partnerships with larger pharmaceutical companies
- Expansion into new indications
- Growing demand for immunotherapies
Threats
- Clinical trial failures
- Competition from other immunotherapy companies
- Regulatory hurdles
- Patent challenges
Competitors and Market Share
Key Competitors
- MRK
- BMY
Competitive Landscape
Immutep competes with large pharmaceutical companies in the immunotherapy space. Its advantage lies in its specific LAG-3 technology, but it faces challenges due to limited resources and the need for clinical trial success.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been characterized by progress in clinical trials and expansion of the pipeline.
Future Projections: Future growth is dependent on the success of clinical trials and regulatory approvals. Analyst estimates vary, but positive trial outcomes could lead to significant stock price appreciation.
Recent Initiatives: Recent initiatives include expanding clinical trials, forming partnerships, and seeking regulatory guidance.
Summary
Immutep is a promising biotechnology company pioneering LAG-3 immunotherapy. Its lead product Efti holds potential, pending successful trial outcomes. The company faces competition from larger players and relies on clinical trial progress. Future growth depends on regulatory approvals and strategic partnerships. The company should carefully watch financial resources.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Immutep Ltd Investor Relations
- SEC Filings
- Industry Reports
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Investment decisions should be made based on individual circumstances and consultation with a financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Immutep Ltd ADR
Exchange NASDAQ | Headquaters Sydney, NSW, Australia | ||
IPO Launch date 2012-04-17 | CEO, MD, CFO, Chief Business Officer & Executive Director Mr. Marc Voigt | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://www.immutep.com |
Full time employees - | Website https://www.immutep.com | ||
Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company's product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L NSCLC); TACTI-003, which is in phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (HNSCC); INSIGHT-005 which is in phase I for metastatic urothelial carcinoma; TACTI-002, which in phase II trial for the treatment NSCLC and HNSCC; AIPAC-003, which is in phase II/III clinical trial to treat metatastic breast cancer; and EFTISARC-NEO, which is in phase II clinical trial for the treatment of soft tissue sarcoma. It also develops INSIGHT-003, which is in phase I trial 1L non squamous NSCL; INSIGHT-005 that is in phase I to treat metastatic urothelial cancer; IMP761, which is in phase I Trial to treat autoimmune disease; IMP731 for oncology and autoimmune diseases; and LAG525. Immutep has collaboration with Merck & Co., Inc., EOC Pharma, Novartis, and Laboratory Corporation of America Holdings. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is based in Sydney, Australia.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.